Shanghai Henlius Biotech (HKG:2696) said the United States Food and Drug Administration approved its investigational new drug application of innovative small molecular HLX99, a Monday bourse filing said.
The drug is a small molecule coupled chemical drug and is purposed for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that causes loss of muscle innervation.